IL-2 injections bolster the immune system of HIV-1-infected adults

The Lancet ◽  
1997 ◽  
Vol 349 (9057) ◽  
pp. 1003
Author(s):  
Marilynn Larkin
Keyword(s):  
Immune System ◽  
Hiv 1

scholarly journals The Relationships between HIV-1 Infection, History of Methamphetamine Use Disorder, and Soluble Biomarkers in Blood and Cerebrospinal Fluid

Viruses ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 1287
Author(s):  
T. Walter ◽  
Jennifer Iudicello ◽  
Debra Cookson ◽  
Donald Franklin ◽  
Bin Tang ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Immune System ◽  
Public Health Problem ◽  
Control Group ◽  
Csf Biomarkers ◽  
Immune System Dysfunction ◽  
Immune Biomarkers ◽  
Plasma Factor ◽  
History Of ◽  
Hiv 1

Methamphetamine (METH) use disorder is highly prevalent among people with HIV (PWH) and is a significant public health problem. HIV and METH use are each associated with immune system dysfunction; however, the combined effects on the immune system are poorly understood. This cross-sectional project measured soluble immune biomarkers in plasma and cerebrospinal fluid (CSF) collected from a control group, people with a history of a METH use disorder (METH+), PWH with no history of METH use disorder (HIV+), and PWH with a history of METH use disorder (HIV+/METH+). HIV, METH, and immune dysfunction can also be associated with affective and cognitive deficits, so we characterized mood and cognition in our participants. Two factor analyses were performed for the plasma and CSF biomarkers. Plasma IL-8, Ccl2, VEGF, and 8-isoprostane loaded onto one factor that was highest in the HIV+/METH+ group (p < 0.047) reflecting worse inflammation, vascular injury, and oxidative stress. This plasma factor was also negatively correlated with delayed recall (R = −0.49, p = 0.010), which was worst in the HIV+/METH+ group (p = 0.030 compared to the control group). Overall, these data implicate that combined HIV-1 infection and METH use may exacerbate inflammation, leading to worse cognition.

The maturing immune system: implications for development and testing HIV-1 vaccines for children and adolescents

AIDS ◽  
2006 ◽  
Vol 20 (4) ◽  
pp. 483-494 ◽  
Author(s):  
Heather B Jaspan ◽  
Stephen D Lawn ◽  
Jeffrey T Safrit ◽  
Linda-Gail Bekker
Keyword(s):  
Immune System ◽  
Children And Adolescents ◽  
Vaccines For Children ◽  
Hiv 1

scholarly journals Defining HIV-1 Envelope N-Glycan Microdomains through Site-Specific Heterogeneity Profiles

2018 ◽  
Vol 93 (1) ◽  
Author(s):  
Audra A. Hargett ◽  
Qing Wei ◽  
Barbora Knoppova ◽  
Stacy Hall ◽  
Zhi-Qiang Huang ◽  
...  
Keyword(s):  
Immune System ◽  
Immune Evasion ◽  
Immune Escape ◽  
High Resolution Mass Spectrometry ◽  
National Laboratory ◽  
Site Specific ◽  
Los Alamos National Laboratory ◽  
Glycosylation Sites ◽  
Env Protein ◽  
Hiv 1

ABSTRACT The HIV-1 envelope (Env) glycans shield the surface of Env from the immune system and form integral interactions important for a functional Env. To understand how individual N-glycosylation sites (NGS) coordinate to form a dynamic shield and evade the immune system through mutations, we tracked 20 NGS in Env from HIV-transmitted/founder (T/F) and immune escape variants and their mutants involving the N262 glycan. NGS were profiled in a site-specific manner using a high-resolution mass spectrometry (MS)-based workflow. Using this site-specific quantitative heterogeneity profiling, we empirically characterized the interdependent NGS of a microdomain in the high-mannose patch (HMP). The changes (shifts) in NGS heterogeneity between the T/F and immune escape variants defined a range of NGS that we further probed for exclusive combinations of sequons in the HMP microdomain using the Los Alamos National Laboratory HIV sequence database. The resultant sequon combinations, including the highly conserved NGS N262, N448, and N301, created an immune escape map of the conserved and variable sequons in the HMP microdomain. This report provides details on how some clustered NGS form microdomains that can be identified and tracked across Env variants. These microdomains have a limited number of N-glycan-sequon combinations that may allow the anticipation of immune escape variants. IMPORTANCE The Env protein of HIV is highly glycosylated, and the sites of glycosylation can change as the virus mutates during immune evasion. Due to these changes, the glycan location and heterogeneity of surrounding N-glycosylation sites can be altered, resulting in exposure of different glycan or proteoglycan surfaces while still producing a viable HIV variant. These changes present a need for vaccine developers to identify Env variants with epitopes most likely to induce durable protective responses. Here we describe a means of anticipating HIV-1 immune evasion by dividing Env into N-glycan microdomains that have a limited number of N-glycan sequon combinations.

Inhibitory KIR/HLA incompatibility between sexual partners confers protection against HIV-1 transmission

Blood ◽  
2013 ◽  
Vol 121 (7) ◽  
pp. 1157-1164 ◽  
Author(s):  
Wim Jennes ◽  
Sonja Verheyden ◽  
Julie W. Mertens ◽  
Makhtar Camara ◽  
Moussa Seydi ◽  
...  
Keyword(s):  
Immune System ◽  
Nk Cells ◽  
Sexual Partners ◽  
Infected Partner ◽  
Key Points ◽  
Hiv 1

Key Points HIV-1 transmission is influenced by the compatibility of sexual partners for two immune system genes, KIR and HLA. KIR/HLA incompatibility likely allows alloreactive NK cells from the exposed partner to reject incoming cells from the HIV-1–infected partner.

scholarly journals OA06-05. Adaptation of HIV-1 to the human immune system at the population level is driven by protective HLA-B alleles

Retrovirology ◽  
2009 ◽  
Vol 6 (S3) ◽  
Author(s):  
IM Schellens ◽  
M Navis ◽  
HW van Deutekom ◽  
B Boeser-Nunnink ◽  
B Berkhout ◽  
...  
Keyword(s):  
Immune System ◽  
Population Level ◽  
Human Immune System ◽  
Human Immune ◽  
Hiv 1

Cutaneous manifestations of HIV-1 infection

1995 ◽  
Vol 85 (7) ◽  
pp. 362-374 ◽  
Author(s):  
O Memar ◽  
R Cirelli ◽  
P Lee ◽  
SK Tyring
Keyword(s):  
Human Immunodeficiency Virus ◽  
Immune System ◽  
Virus Infection ◽  
Hiv Infection ◽  
Cutaneous Manifestations ◽  
Immunodeficiency Virus ◽  
The Status ◽  
History Of ◽  
Hiv 1

Infection with the human immunodeficiency virus (HIV) leads to a chronic disarmament of the immune system. The process is progressive, having different manifestations as the status of the immune system slowly deteriorates. Some of the most common manifestations of HIV infection are cutaneous in origin, and they can have infectious, neoplastic, or noninfectious or non-neoplastic etiologies. A brief history of HIV is given, and the most common cutaneous presentations of the virus infection of interest to podiatrists are outlined.

Photopheresis in HIV-1 Infected Patients (pt) using Benzoporphyrin Derivative (BPD-MA) Induces Apoptosis in CD4 Cells, Increases Intracellular Expression of Chemokines and Decreases HIV Infectivity and Viral Load.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 3836-3836
Author(s):  
Zale P. Bernstein ◽  
Thomas Dougherty ◽  
Stanley A. Schwartz ◽  
Sandra Gollnick ◽  
Carleton Stewart ◽  
...  
Keyword(s):  
Viral Load ◽  
Immune System ◽  
Ex Vivo ◽  
Light Exposure ◽  
Area Under The Curve ◽  
Additional Patient ◽  
Viral Control ◽  
Viral Loads ◽  
Hiv 1

Abstract HIV is able to elude both cellular and humoral arms of the immune system; thereby making viral control difficult. Extra corporeal photochemotherapy (ECP) or photopheresis is an immunomodulatory therapy in which lymphocytes are reinfused into the host after exposure to a photoactive compound and ultraviolet A light. It is an effective therapeutic approach to several disorders of the immune system including acute and chronic graft-versus-host disease, scleroderma, and cutaneous T-cell lymphoma. This process may offer a novel approach to viral control with minimal or no toxicity. We initiated an ex vivo and subsequently a clinical pilot trial utilizing Benzoporphyrin Derivative as the photosensitive compound. Ex vivo dosing studies identified the minimum energy levels of light exposure and concentrations of BPD that eradicated both cell-free and cell-associated HIV-1 infectivity without destroying the virus particles or infected leukocytes. Leukocytes so treated remained viable. They did demonstrate altered cytokine and chemokine expression with apoptosis induced in a minority of CD4 but not CD8 positive cells. A pilot in vivo, 24 week clinical trial in seven HIV-1 infected patients (all were required, upon entry, to have viral loads of > 10,000) using the photopheresis parameters established above demonstrated that the treatment was well tolerated and beneficial. Three individuals who had rapidly rising viral loads prior to initiating therapy stabilized once treatment began. Two of which had a (sustained) greater than.5 log decrement and 5 had stable plasma viral loads (less than a.5 log increment or decrement) with varied effects on absolute CD4 and CD8 positive lymphocytes counts. One subject achieved a greater than 1 log decrement in HIV-1 plasma viral load also developed undetectable in vivo cell-free and cell-associated HIV-1 infectivity while demonstrating an increased in vitro lymphocyte mitogen stimulation index. Subsequently, under amended protocol 3 additional 12 month courses were administered to one additional patient and two of the previous enrollees. The area under the curve for viral load (viral load x # of weeks) for these ten courses of therapy showed a significant decrease from pre to post therapy (p 0.007). There were no significant changes in CD4 or CD8 numbers area under the curve (CD4 number # of weeks and CD8 number x # of weeks). None of the subjects developed an AIDS defining illness during the course of therapy nor were there any treatment associated toxicities. These studies suggest that ECP augments activity of various arms of the immune system without any significant toxicity and may be effective in controlling HIV replication. We have now instituted a Phase II study utilizing long-term photopheresis (twice monthly for 48 weeks) to further determine efficacy and mechanism of activity.

Sign in / Sign up

Export Citation Format

Share Document